SLC5A2 and type 2 diabetes mellitus: To the best of our knowledge, this is the first case report of EC associated with the use of a sodium-glucose cotransporter 2 inhibitor (SGLT2i).<h4>Case report</h4>A 62-year-old man with T2DM treated with an SGLT2i developed EC.